Transfusion Medicine Reviews
Volume 20, Issue 2 , Pages 110-140, April 2006

Bystander Immune Cytolysis

  • Lawrence D. Petz

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Lawrence D. Petz, MD, StemCyte International Cord Blood Center, 400 Rolyn Place, Arcadia, CA 91007.

University of California Los Angeles (UCLA) Medical Center, Los Angeles, CA

StemCyte International Cord Blood Center, Arcadia, CA

In addition to alloimmune and autoimmune cell lysis, a third category of immune destruction of blood cells should be recognized. This additional immunologic response occurs when cells or tissues are injured by immunologic reactions in which the cells act as “innocent bystanders.” One mechanism by which an immune response to an exogenous antigen leads to the destruction of autologous blood cells is the temporary development of autoantibodies. This is actually an alloimmune reaction which results in a temporary state of “pseudo”-autoimmunity. Although originally described as a type of hemolysis of autologous cells, the concept of bystander immune cytolysis has been extended to include other instances in which immune destruction of cells is caused by antibody that is not developed in response to intrinsic antigens on the cell being lysed. In recent years, compelling data have been presented documenting bystander immune cytolysis in a number of different clinical settings, and efforts have been made to define the mechanisms by which this occurs. Physicians must be aware that some examples of immune lysis of autologous cells are, in reality, examples of temporary bystander immune cytolysis rather than true autoimmune disease. Furthermore, some alloimmune hemolytic reactions can result in lysis of bystander cells.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0887-7963(05)00108-2

doi:10.1016/j.tmrv.2005.11.002

Transfusion Medicine Reviews
Volume 20, Issue 2 , Pages 110-140, April 2006